H.C. Wainwright initiated coverage of Senti Bio (SNTI) with a Buy rating and $12 price target The firm believes the company’s allogeneic CAR-NK cell therapy platform has the potential to treat several cancer types including hematologic malignancies and solid tumors. It views Senti as an “underappreciated CAR-NK player with a differentiated platform with a near-term catalyst” in Q4.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off